Steven Cohen's TGTX Position Overview
Steven Cohen (via Point72 Asset Management, L.P.) currently holds 231,358 shares of TG Therapeutics, Inc. (TGTX) worth $6.9 M, representing 0.01% of the portfolio. First purchased in 2018-Q1, this medium-term investment has been held for 17 quarters.
Based on 13F filings, Steven Cohen has maintained a strategic position in TGTX, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2019, adding 1.28 M shares. Largest reduction occurred in Q3 2019, reducing 680,155 shares.
Analysis based on 13F filings available since 2013 Q2
Steven Cohen's TG Therapeutics (TGTX) Holding Value Over Time
Track share changes against reported price movement
Quarterly TG Therapeutics (TGTX) Trades by Steven Cohen
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -134,474 | Reduce 36.76% | 231,358 | $29.81 |
| Q3 2025 | -351,678 | Reduce 49.01% | 365,832 | $36.13 |
| Q2 2025 | +717,510 | New Buy | 717,510 | $35.99 |
| Q3 2024 | -585,873 | Sold Out | 0 | $0.00 |
| Q2 2024 | +585,873 | New Buy | 585,873 | $17.79 |
| Q4 2023 | -611,678 | Sold Out | 0 | $0.00 |
| Q3 2023 | +293,408 | Add 92.19% | 611,678 | $8.36 |
| Q2 2023 | +297,589 | Add 1438.95% | 318,270 | $24.84 |
| Q1 2023 | +20,681 | New Buy | 20,681 | $15.04 |
| Q4 2022 | -437,200 | Sold Out | 0 | $0.00 |
| Q3 2022 | +437,200 | New Buy | 437,200 | $5.92 |
| Q4 2019 | -19,845 | Sold Out | 0 | $0.00 |
| Q3 2019 | -680,155 | Reduce 97.16% | 19,845 | $5.59 |
| Q2 2019 | -578,900 | Reduce 45.27% | 700,000 | $8.65 |
| Q1 2019 | +1.28 M | New Buy | 1.28 M | $8.04 |
| Q2 2018 | -603,800 | Sold Out | 0 | $0.00 |
| Q1 2018 | +603,800 | New Buy | 603,800 | $14.20 |
Steven Cohen's TG Therapeutics Investment FAQs
Steven Cohen first purchased TG Therapeutics, Inc. (TGTX) in Q1 2018, acquiring 603,800 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen has held TG Therapeutics, Inc. (TGTX) for 17 quarters since Q1 2018.
Steven Cohen's largest addition to TG Therapeutics, Inc. (TGTX) was in Q1 2019, adding 1,278,900 shares worth $10.28 M.
According to the latest 13F filing for Q4 2025, Steven Cohen's firm, Point72 Asset Management, L.P., owns 231,358 shares of TG Therapeutics, Inc. (TGTX), valued at approximately $6.9 M.
As of the Q4 2025 filing, TG Therapeutics, Inc. (TGTX) represents approximately 0.01% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.
Steven Cohen's peak holding in TG Therapeutics, Inc. (TGTX) was 1,278,900 shares, as reported at the end of Q1 2019.